Loading...
XNAS
TBPH
Market cap877mUSD
Jul 10, Last price  
16.93USD
1D
-0.29%
1Q
3.55%
Jan 2017
-46.89%
IPO
-22.94%
Name

Theravance Biopharma Inc

Chart & Performance

D1W1MN
XNAS:TBPH chart
P/E
8.29
P/S
8.17
EPS
2.04
Div Yield, %
—
Shrs. gr., 5y
-3.75%
Rev. gr., 5y
8.38%
Revenues
107m
+66.92%
14,854,000130,145,000226,00011,688,00042,126,00048,648,00015,386,00060,370,00073,414,00071,857,00055,311,00051,346,00057,424,00064,381,000107,464,000
Net income
106m
P
-109,335,000-9,575,000-156,284,000-237,038,000-182,219,000-190,669,000-285,405,000-215,524,000-236,455,000-278,017,000-199,426,000872,132,000-55,193,000-56,418,000105,895,000
CFO
239m
P
-83,428,000-119,107,000-120,959,000-175,155,000-168,857,000-98,989,000-201,052,000-112,867,000-238,197,000-250,403,000-207,858,000-186,991,000-26,997,000-11,535,000238,541,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
URL
https://www.theravance.com
IPO date
May 16, 2014
Employees
111
Domiciled in
KY
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT